The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2- aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a] isoquinolin-4-one]

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 840-848

  Boswell Smith, Victoria ^a   Spina, Domenico ^a   Oxford, Alec W ^b   Comer, Mike B ^b   Seeds, Esther A ^a   Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[6,7 DIHYDRO 2 (2,6 DIISOPROPYLPHENOXY) 9,10 DIMETHOXY 4H PYRIMIDO(6,1A)ISOQUINOLIN 4 ONE]; [9,10 DIMETHOXY 2 (2,4,6 TRINETHYLPHENYLIMINO) 3 (N CARBAMOYL 2 AMINOETHYL) 3,4,6,7 TETRAHYDRO 2H PYRIMIDO(6,1A)ISOQUINOLIN 4 ONE]; HISTAMINE; LACTOSE; LONG ACTING DRUG; OVALBUMIN; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHYTOHEMAGGLUTININ; PLASMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ELECTRIC FIELD; ELECTROSTIMULATION; EOSINOPHIL; EXPOSURE VARIABLE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MONONUCLEAR CELL; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; TRACHEA;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AIRWAY RESISTANCE; ANIMALS; BLOOD PRESSURE; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; ELECTRIC STIMULATION; GUINEA PIGS; HUMANS; ISOQUINOLINES; LUNG; MALE; MONOCYTES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; PHYTOHEMAGGLUTININS; PLATELET AGGREGATION INHIBITORS; PNEUMONIA; PYRIMIDINONES; TETRAHYDROISOQUINOLINES; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745939122     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.099192     Document Type: Article

References (41)

1. Aoki M, Yamamoto S, Kobayashi M, Ohga K, Kanoh H, Miyata K, Honda K, and Yamada T (2001) Anti-asthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. J Pharmacol Exp Ther 297:165-173.
2. Banner KH, Marchini F, Buschi A, Moriggi E, Semeraro C, and Page CP (1995) The effect of selective phosphodiesterase inhibitors in comparison with other antiasthma drugs on allergen-induced eosinophilia in guinea-pig airways. Pul Pharmacol 8:37-42.
3. Bardin PG, Doward MA, Lampe FC, Franke B, and Holgate ST (1998) Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 45:387-391.
4. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
5. Bateman ED, Izquirdo JL, Vetter N, Schmid-Wirlitsch C, and Bredenbroker D (2003) Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma (Abstract). Eur Respir J 22 (Suppl 45):1393.
6. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290.
7. Coleman RA, Nials AT, Rabe KF, Vardey CJ, and Watson N (1996) Isolated, electrically-stimulated airway preparations-their use in determining betaadrenoceptor agonist activity. Pulm Pharmacol 9:107-117.
8. Cortijo J, Bou J, Beleta J, Cardelus I, Llenas J, Morcillo E, and Gristwood RW (1993) Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 108:562-568.
9. Crocker IC, Townley RG, and Khan MM (1996) Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31:223-235.
10. de Boer J, Philpott AJ, Van Amsterdam RG, Shahid M, Zaagsma J, and Nicholson CD (1992) Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 106:1028-1034.
11. Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108:671-680.
12. Evans TW, Rogers DF, Aursudkij B, Chung KF, and Barnes PJ (1989) Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig. Clin Sci (Lond) 76:479-485.
13. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958.
14. Gozzard N, Herd CM, Blake SM, Holbrook M, Hughes B, Higgs GA, and Page CP (1996) Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 117:1405-1412.
15. Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, and Rabe KF (2003) Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 16:115-120.
16. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
17. Howell LL (1993) Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 266:894-903.
18. Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G, et al. (1996) The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br J Pharmacol 118:1183-1191.
19. Jones NA, Boswell-Smith V, Lever R, and Page CP (2005) The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18:93-101.
20. Kuss H, Hoefgen N, Johanssen S, Kronbach T, and Rundfeldt C (2003) In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 307:373-385.
21. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-175.
22. Martinez FD (2005) Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 353:2637-2639.
23. Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T, and Matsuda T (1999) Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 160:817-820.
24. Naline E, Qian Y, Advenier C, Raeburn D, and Karlsson JA (1996) Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 118:1939-1944.
25. Ortiz JL, Valles JM, Marti-Cabrera M, Cortijo J, and Morcillo EJ (1996) Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigeninduced airway hyperreactivity, eosinophil accumulation and microvascular leakage in guinea pigs. Naunyn-Schmiedeberg's Arch Pharmacol 353:200-206.
26. Oxford AW and Jack D (2004) inventor, Vernalis Ltd, assignee. Derivatives of pyrimido [6-1-A] isoquinolin-4-one. U.S. patent 200417182, 2004 Sept. 21.
27. Packer M, Corker JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bonner WJ, Elkgim U, and Kukin MC (1991) Effect of oral Milrinone on mortality in severe chronic heart failure: The Promise Study Research Group. N Engl J Med 325:1468-1475.
28. Rabe KF, Magnussen H, and Dent G (1995) Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 8:637-642.
29. Raeburn D, Souness JE, Tomkinson A, and Karlsson JA (1993) Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. Prog Drug Res 40:9-32.
30. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, and Polson JB (1991) Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42:869-877.
31. Seeds EA, Kilfeather S, Okiji S, Schoupe TS, Donigi-Gale D, and Page CP (1995) Role of lipoxygenase metabolites in platelet-activating factor- and antigen-induced bronchial hyperresponsiveness and eosinophil infiltration. Eur J Pharmacol 293:369-376.
32. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, and Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284:L279-L289.
33. Spina D (2004) The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 3:231-236.
34. Spina D, Ferlenga P, Biasini I, Moriggi E, Marchini F, Semeraro C, and Page CP (1998) The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci 62:953-965.
35. Spina D, Harrison S, and Page CP (1995) Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Br J Pharmacol 116:2334-2340.
36. Tigani B, Cannet C, Zurbrugg S, Schaeublin E, Mazzoni L, Fozard JR, and Beckmann N (2003) Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging. Br J Pharmacol 140:239-246.
37. Torphy TJ (1998) Phosphodiesterase isoenzymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370.
38. Torphy TJ, Burman M, Huang LB, and Tucker SS (1988) Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. J Pharmacol Exp Ther 246:843-850.
39. Torphy TJ and Undem BJ (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.
40. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, and Torphy TJ (1998) Anti-asthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 287:988-995.
41. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, and Torphy TJ (1994) Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 270:250-259.